The Checkmate 143 clinical trial (NCT02017717) reported comparable median OS between nivolumab-treated and bevacizumab-treated control patients.9 Similarly, in the Checkmate 498 study (NCT02617589), combined PD-1 blockade and radiotherapy in newly diagnosed GBM patients with unmethylated MGMT promoter did not improve survival.10 Lastly, nivolumab in combination with temozolomide (TMZ) and radiotherapy was found not to be superior to TMZ, radiotherapy, and placebo in newly diagnosed GBM patients with methylated MGMT promoter.11 Here, MGMT is linked to glioblastoma.